MedinCell S.A.
MEDCL.PA · PAR
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -27.9% | 70.7% | 150.6% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 0% | 100% | 100% | 91.3% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €0 | €0 | -€0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -78.8% | -20.6% | -79.8% | -318.6% |
| Other Income/Exp. Net | -€0 | -€0 | -€0 | -€0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | -€0 | €0 | €0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -138.5% | -24% | -154.4% | -448.3% |
| EPS | -0.49 | -0.12 | -0.5 | -0.58 |
| % Growth | -308.3% | 76% | 13.8% | – |
| EPS Diluted | -0.49 | -0.12 | -0.5 | -0.58 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -127.5% | -24.5% | -76.9% | -306.8% |